Experimental Pathology Laboratories, Inc. (EPL) has acquired Aclairo Pharmaceutical Development Group, Inc. (Aclairo).
Dr. Jerry Hardisty, EPL's President and CEO, said the acquisition leverages EPL's global presence and renowned preclinical histopathology expertise with Aclairo's specialized consultation services. The combination offers clients unparalleled nonclinical and clinical drug metabolism and pharmacokinetics (DMPK) services.
"Aclairo's team of industry and ex-FDA experts have developed a specialized consultancy in drug and device development strategy with breadth and depth in the biologic, pharmaceutical and device arenas. Their expertise includes regulatory strategy and oversight, pharmacology, toxicology, DMPK, and overall program design, placement, management and interpretation," said Dr. Hardisty.
"EPL and Aclairo share a similar market and are focused on providing a tailored solution for each client. The combination of each organization's strengths will help deliver a more comprehensive product for our clients."
Aclairo provides independent and objective nonclinical, regulatory, and clinical ADME/DMPK expert strategy and implementation to the pharmaceutical and drug device industries.
Keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.